The business is running at maximum dose. The stock may already price the full response.
Revenue is up 48% and guidance has been raised twice, yet the shares sit at an all-time high only ~1% below the Street’s mean target. The Q3 print lands Oct 29. The question: does volume keep outrunning falling net price?
Gray = LLY price through Oct 22, 2026, a 12-month window drawn from dated closes and disclosures (straight segments between anchors, not daily data); colored paths = scenario midpoints, probability-weighted (bear 30% · base 45% · bull 25%). Bear-tilted because the stock is at a record, trades ~30% above Morningstar fair value, and sits at the Street mean target. Open circle = Street mean ~$1,317. Scenarios are illustrative frameworks, not forecasts.
Re-weight the scenarios
Make the odds yours. Drag to set bear and bull (base takes the remainder); the blended target, the dotted line on the chart, and the prob-weighted rows below update live.
Six analyst lenses, six answers
Synthesized perspectives with their own 12-month targets (panel mean ~$1,192 vs Street ~$1,317). Not real people or real firm ratings.
The Volume Compounder
Revenue +48% at $80B TTM, Mounjaro +91%, ex-US +80% on China NRDL, retatrutide filing Q1 2027. Earnings still compounding 20%+ through 2028.
The Cash Counter
TTM FCF $18.2B is only a ~1.6% yield on a $1.17T cap, debt is $54.9B and capex is $9.9B and rising. Quality is superb; the price already pays for it.
The Price-Taker Thesis
Net price is falling (US price −3% even after rebate true-ups), Medicare and cash-pay channels reset the base, and Novo’s oral Wegovy led Foundayo to market.
The Capacity Moat
Ten new US sites since 2020 and a $5B Virginia plant: manufacturing scale and the dual-incretin franchise are the barrier. Share of GLP-1 market was 58% in Q3 2025.
The Breakout
Record high Oct 20 on a 97% 52-wk range position; forward P/E ~33x vs a 5-yr average ~40x. Momentum favors holders, but RSI-type overbought risk into Oct 29.
The Policy Meter
Medicare GLP-1 Bridge started July, tariff grace tied to price deals, China export threats in the news. Sector rotation into defensives is a tailwind that can reverse.
Wall Street 12-month price targets
Sorted low to high; dashed line is today’s $1,306.69. Most recent targets sit within ~10% of the price.
Consensus per TradingKey (Oct 22, 2026): mean $1,316.96, high $1,600, low $891.22; Yahoo shows a $1,331.55 one-year estimate; MarketBeat counts 1 Strong Buy, 24 Buy, 3 Hold, 1 Sell. HSBC, Redburn and Berenberg targets are older (dates shown) and may have changed.
Where the dose-response leads
Scenario price = EPS × exit multiple. Returns vs. $1,306.69. Illustrative frameworks, not forecasts.
1 Year
Mid-20272 Years
Mid-20283 Years
Mid-20295 Years
Mid-2031▸ Bull case — show the assumptions & math
▸ Base case — show the assumptions & math
▸ Bear case — show the assumptions & math
Revenue, capex, free cash flow & debt ($B)
Cash generation has exploded, but so has the capital it takes to make the drug.
Revenue $34.1B / $45.0B / $65.2B / $79.7B TTM; capex $3.4B / $5.1B / $7.8B / $9.9B; FCF $0.8B / $3.8B / $9.0B / $18.2B; debt $25.2B / $33.6B / $42.5B (10-K) and $54.9B at Jun ’26 (aggregator, includes leases). The bull sees FCF compounding; the bear sees capex and debt climbing with it.
EPS path underpinning the targets ($)
Each target is an EPS estimate times an exit multiple. This is the ladder.
Reported non-GAAP: $24.21 (2025, per Lilly) and ~$12.98 (2024). 2026E = guidance midpoint $36.00 (includes $3.03 Q2 IPR&D). 2027E ~$43.50 and 2028E ~$49.10 follow consensus (FY27 earnings ~$38.4B, 2028 average $49.14); 2029–31E extend at consensus growth rates (+11%, +10%, +9%). Base 2031E EPS $65.5 × 24x ≈ $1,572.
The business is still growing
Q2 FY26, year-over-year — read these against a stock at its record.
Unlike a beaten-down name, the disconnect here runs the other way: growth is intact and the stock has re-rated to a record, so the bull no longer has a valuation cushion. Zepbound growth shown per Lilly’s release (44%); some outlets print 46%.
Bull vs. Bear
Core debate: volume growth versus a shrinking net price on the same molecule.
▲ THE BULL CASE
- Growth is not slowing. Q2 revenue +48% to $22.97B vs $20.82B expected; FY26 guide raised twice to $85–87B (Aug 5).
- Profit outruns sales. Non-GAAP EPS +33% despite $3.03 of IPR&D; TTM operating margin 49.7% vs 42.1% a year earlier.
- Pipeline depth. Retatrutide has a complete obesity data package with an FDA filing planned Q1 2027; Foundayo cleared the EMA committee Oct 15.
- Global leg is just starting. Ex-US revenue +80% with Mounjaro on China’s NRDL; Mounjaro international +172%.
- Capacity is the moat. $5B Virginia groundbreaking (Oct 22), $4.5B more in Indiana, 10 new US sites since 2020.
- Estimates still rising. Goldman ($1,413), Morgan Stanley ($1,430) and Cantor ($1,440) all lifted targets in October ahead of the Oct 29 print.
▼ THE BEAR CASE
- Priced for perfection. 43.9x trailing and ~33x forward earnings; Morningstar fair value ~$980, a ~30% premium; Street mean target ($1,317) is only ~1% above the price.
- Net price is shrinking. US Q2 price −3%, and about −9% without rebate true-ups; Medicare GLP-1 Bridge began in July.
- Oral race is not won. Foundayo did $98M in Q2 vs about $500M for Novo’s Wegovy pill, which launched first.
- Capital intensity climbing. TTM capex $9.9B (vs $3.4B in 2023); total debt $54.9B incl. leases vs $25.2B in 2023.
- Earnings are noisy. Big BD deals: $3.03 per share of acquired IPR&D hit Q2; more deals are likely.
- Concentration. Mounjaro + Zepbound are ~$14.8B of $22.97B in Q2; a safety, policy or supply shock hits most of the company at once.
Risk map — likelihood × impact
The hot corner — likely and high-impact — is net-price erosion; the genuine tail is a class-wide safety shock.
- IPR&D noise
- Multiple de-rating
- Capex & leverage
- Net-price erosion
- Oral launch
- Retatrutide setback
- China / trade
- Class safety shock
Net-price erosion
Medicare, cash-pay and payer pressure cut net price faster than volume grows, compressing revenue per script and margin.
Multiple de-rating
At ~33x forward the stock sits on growth durability; a growth wobble resets the multiple toward 25x.
Capex & leverage creep
Capex and debt keep climbing, trimming free cash flow conversion and the buyback capacity.
IPR&D noise
Business-development charges swing quarterly EPS and can mask the underlying beat.
Oral launch shortfall
Foundayo fails to scale against Novo’s earlier oral Wegovy, leaving the oral TAM to the competitor.
Retatrutide setback
A safety or label surprise delays the Q1 2027 filing and the next growth leg.
Class safety shock
A GLP-1 class safety finding or regulatory action reprices the whole franchise.
China / trade shock
Export threats or tariffs hit the fastest-growing ex-US line.
The jargon, decoded
Hover the dotted terms in the metrics, or scan the working definitions.
- Net price / gross-to-net
- Revenue per prescription after rebates and discounts; falling net price is the bear’s core worry.
- GLP-1 / incretin
- Drug class that mimics gut hormones to cut appetite and blood sugar; Mounjaro and Zepbound are dual GIP/GLP-1.
- Acquired IPR&D
- Up-front cost of buying unfinished drug assets, expensed at once ($3.03/share in Q2’26).
- Non-GAAP EPS
- Earnings per share excluding items management treats as non-core; Lilly still includes IPR&D.
- Free cash flow
- Operating cash flow minus capex; ~$18.2B TTM, a ~1.6% yield at today’s market cap.
- Forward P/E
- Price divided by next-12-month earnings estimate; ~33x vs a ~40x five-year average.
- Exit multiple
- P/E assumed at the forecast end; times EPS gives the scenario price.
- Prob-weighted
- Each scenario price times its probability, summed into one expected value.